Brca2 deficiency and Trp53 deregulation in pancreatic cancer: Implications for therapeutic targeting

Cancer Biology and Therapy

Volumn 11, Issue 11, 2011, Pages 969-973

  Yee, Nelson S ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Brca2; Pancreatic cancer; Targeting; Trp53; Tumorigenesis

Indexed keywords

BRCA2 PROTEIN; CARBOPLATIN; CISPLATIN; DOUBLE STRANDED DNA; GEMCITABINE; K RAS PROTEIN; OLAPARIB; PROTEIN P53; TRP53; UNCLASSIFIED DRUG;

ADD ON THERAPY; BINDING SITE; BREAST CANCER; CANCER DIAGNOSIS; CANCER GROWTH; CANCER MORTALITY; CARCINOGENESIS; DNA REPAIR; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; GENE MUTATION; GENETIC TRANSCRIPTION; GENOMIC INSTABILITY; HUMAN; NONHUMAN; NOTE; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREATIC INTRAEPITHELIAL NEOPLASIA; PROSTATE CANCER;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; BRCA2 PROTEIN; CARCINOMA, PANCREATIC DUCTAL; ENZYME INHIBITORS; GENETIC ASSOCIATION STUDIES; MICE; PANCREATIC NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79957820148     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.11.16573     Document Type: Note

References (50)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;59:277-300.
2. Hidalgo M. Pancreatic cancer. N Engl J Med 2010; 362:1605-17.
3. Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. Clin Cancer Res 2000; 6:2969-72. (Pubitemid 30637716)
4. Hruban RH, Fukushima N. Pancreatic adenocarcinoma: update on the surgical pathology of carcinomas of ductal origin and PanINs. Modern Path 2007; 20:S61-70.
5. Yee NS, Furth EE, Pack M. Clinicopathologic and molecular features of pancreatic adenocarcinoma associated with Peutz-Jeghers syndrome. Cancer Biol Ther 2003; 2:38-47.
6. Yee NS. Zebrafish as a biological system for identifying and evaluating therapeutic targets and compounds. In Drug discovery in pancreatic cancer. 2010; pp. 95-112. (edited by Han H. and Grippo P.J.) New York: Springer.
7. Chun SG, Yee NS. Werner's syndrome as a hereditary risk factor for exocrine pancreatic cancer: Potential role of WRN in pancreatic tumorigenesis and patienttailored therapy. Cancer Biol Ther 2010, 10:430-7.
8. Goggins M, Schutte M, Lu J, Moskaluk CA, Weinstein CL, Petersen GM, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996; 56:5360-4. (Pubitemid 27011364)
9. Lal G, Liu G, Schmocker B, Kaurah P, Ozcelik H, Narod SA, et al. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germline p16, BRCA1, and BRCA2 mutations. Cancer Res 2000; 60:409-16. (Pubitemid 30070770)
10. Goggins M, Hruban RH, Kern SE. BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. Am J Pathol 2000; 156:1767-71. (Pubitemid 30646713)
11. Murphy KM, Brune KA, Griffin C, Sollenberger JE, Petersen GM, Bansal R, et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 2002; 62:3789-93. (Pubitemid 34728862)
12. Naderi A, Couch FJ. BRCA2 and pancreatic cancer. Int J Gastrointes Cancer 2002; 31:99-106. (Pubitemid 36330111)
13. Hahn SA, Greenhalf B, Ellis I, Sina-Frey M, Rieder H, Korte B, et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 2003; 95:214-21. (Pubitemid 36240634)
14. Hruban RH, Klein AP, Eshleman JR, Axilbund JE, Goggins M. Familial pancreatic cancer: from genes to improved patient care. Expert Rev Gastroenterol Hepatol 2007; 1:81-8
15. Venkitaraman AR. Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment. Ann Rev Pathol 2009; 4: 461-87.
16. Tutt A, Bertwistle D, Valentine J, Gabriel A, Swift S, Ross G, et al. Mutation in Brca2 stimulates errorprone homology-directed repair of DNA doublestrand breaks occurring between repeated sequences. EMBO J 2001; 17: 4704-16. (Pubitemid 32848624)
17. Redston MS, Caldas C, Seymour AB, Hruban RH, da Costa L, Yeo CJ, Kern SE. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994; 54:3025-33. (Pubitemid 24187791)
18. Brady CA, Attardi LD. p53 at a glance. J Cell Sci 2010; 123:2527-32.
19. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, et al. Pre-invasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003; 4:437-50. (Pubitemid 38050041)
20. Hingorani, SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005; 7:469-83. (Pubitemid 40719130)
21. Brugarolas J, Jacks T. Double indemnity: p53, BRCA and cancer. p53 mutation partially rescues developmental arrest in Brca1 and Brca2 null mice, suggesting a role for familial breast cancer genes in DNA damage repair. Nat Med 1997; 7:721-2.
22. Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 2001; 29:418-25. (Pubitemid 34326692)
23. Rajagopalana S, Andreevab A, Rutherfordb TJ, Fershta AR. Mapping the physical and functional interactions between the tumor suppressors p53 and BRCA2. Proc Natl Acad Sci 2010; 107:8587-92.
24. Feldmann G, Karikari C, dal Molin M, Duringer S, Detlef VP, Bartsch K, et al. Inactivation of Brca2 Cooperates with Trp53R172H to induce invasive pancreatic ductal adenocarcinomas in mice: A mouse model of familial pancreatic cancer. Cancer Biol Ther 2011; 11:959-68.
25. Petitjean A, Achatz MIW, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007; 26:2157-65. (Pubitemid 46536647)
26. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 Database. Human Mut 2007; 28:622-9. (Pubitemid 46744292)
27. Jonsson J, Carlsson L, Edlund T, Edlund H. Insulinpromoter factor 1 is required for pancreas development in mice. Nature 1994; 371:606-9. (Pubitemid 24315741)
28. Offield MF, Jetton TL, Labosky PA, Ray M, Stein RW, Magnuson MA, et al. PDX-1 is required for pancreatic outgrowth and differentiation of the rostral duodenum. Development 1996; 122:983-95. (Pubitemid 26096002)
29. Stoffers DA, Zinkin NT, Stanojevic V, Clarke WL, Habener JF. Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. Nat Genet 1997; 15:106-10. (Pubitemid 27014961)
30. Yee NS, Yusuff S, Pack M. Zebrafish pdx1 morphant displays defects in pancreas development and digestive organ chirality, and potentially identifies a multipotent pancreas progenitor cell. Genesis 2001; 30:137-40. (Pubitemid 32730759)
31. Park JY, Hong SM, Klimstra DS, Goggins MG, Maitra A, Hruban RH. Pdx1 expression in pancreatic precursor lesions and neoplasms. Appl Immunohistochem Mol Morpho 2011 Feb 10. [Epub ahead of print]
32. Skoulidis F, Cassidy LD, Pisupati V, Jonasson JG, Bjarnason H, Eyfjord JE, et al. Germline Brca2 heterozygosity promotes Kras(G12D)-driven carcinogenesis in a murine model of familial pancreaticcancer. Cancer Cell 2010; 18:499-509.
33. Rowley M, Ohashi A, Mondal G, Mills L, Yang L, Zhang L, et al. Inactivation of Brca2 promotes Trp53- associated byt inhibits KrasG12D-dependent pancreatic cancer development in mice. Gastroenterollogy 2011; DOI: 10.1053/j-gastro.2010.12.039
34. Francis JC, McCarthy A, Thomsen MK, Ashworth A, Swain A. Brca2 and Trp53 deficiency cooperate in the progression of mouse prostate tumourigenesis. PLoS Genet 2010; 6:e1000995.
35. Shive HR, West RR, Embree LJ, Azumab M, Soodc R, Liuc P, Hickstein DD. brca2 in zebrafish ovarian development, spermatogenesis, and tumorigenesis. Proc Natl Acad Sci 2010; 107:19350-5.
36. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434:917-21. (Pubitemid 40559006)
37. Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008; 451:1111-6.
38. Calvert H, Azzariti A. The clinical development of inhibitors of poly(ADP-ribose) polymerase. Ann Oncol 2011; 22 Suppl 1:i53-9.
39. Gottipati P, Vischioni B, Schultz N, Solomons J, Bryant HE, Djureinovic T, et al. Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination- defective cells. Cancer Res 2010; 70:5389-98.
40. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2- deficient tumours with inhibitors of poly(ADPribose) polymerase. Nature 2005; 434:913-7. (Pubitemid 40559005)
41. Drew Y, Mulligan EA, Vong W-T, Thomas HD, Kahn S, Kyle S, et al. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst 2011; 103:334-46.
42. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010; 376:245-51.
43. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376:235-44.
44. O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011; 364:205-14.
45. Cheung CH, Coumar MS, Hsieh HP, Chang JY. Aurora kinase inhibitors in preclinical and clinical testing. Expert Opin Investig Drugs 2009; 18:379-98.
46. Bodvarsdottir SK, Hilmarsdottir H, Birgisdottir V, Steinarsdottir M, Jonasson JG, Eyfjord JE. Aurora-A amplification associated with BRCA2 mutation in breast tumours. Cancer Lett 2007; 248:96-102.
47. Vidarsdottir L, Steingrimsdottir G, Bodvarsdottir SK, Ogmundsdottir HM, Eyfjord JE. Sensitivity of BRCA2 mutated human cell lines to Aurora kinase inhibition. Invest New Drugs 2010; Oct 20. [Epub ahead of print]
48. Li Q, Guntuku S, Cui XS, Matsuoka S, Cortex D, Tamai K, et al. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)M DNA damage checkpoint. Genes Dev 2001; 14:1448-59.
49. Hattori H, Skouldis F, Russell P, Venkitaraman AR. Context dependence of checkpoint kinase 1 as a therapeutic target for pancreatic cancers deficient in the BRCA2 tumor suppressor. Mol Cancer Ther 2011; 10:670-8.
50. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 2009; 9:862-73.